Wedge Capital Management L L P NC cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.1% during the second quarter, Holdings Channel reports. The fund owned 874,039 shares of the medical equipment provider’s stock after selling 234,346 shares during the period. Wedge Capital Management L L P NC’s holdings in Hologic were worth $39,664,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. State Street Corp raised its stake in shares of Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock worth $540,846,000 after buying an additional 189,572 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock worth $172,363,000 after buying an additional 3,269,503 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Hologic by 6.6% in the second quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock worth $155,123,000 after buying an additional 211,550 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock worth $134,668,000 after buying an additional 2,204,085 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock worth $132,440,000 after buying an additional 186,854 shares in the last quarter. 94.46% of the stock is owned by institutional investors and hedge funds.

Hologic, Inc. (HOLX) opened at 38.20 on Friday. The stock has a 50 day moving average price of $43.73 and a 200-day moving average price of $42.89. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80. The stock has a market capitalization of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the prior year, the firm earned $0.51 earnings per share. The firm’s revenue was up 12.4% compared to the same quarter last year. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Wedge Capital Management L L P NC Has $39.66 Million Position in Hologic, Inc. (HOLX)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/wedge-capital-management-l-l-p-nc-has-39-66-million-position-in-hologic-inc-holx/1478066.html.

A number of brokerages recently issued reports on HOLX. Stifel Nicolaus raised their price target on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, May 11th. Jefferies Group LLC reissued a “buy” rating and set a $49.00 price target on shares of Hologic in a research note on Wednesday, June 28th. Bank of America Corporation reissued a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research note on Friday, July 21st. Canaccord Genuity reissued a “buy” rating and set a $53.00 price target on shares of Hologic in a research note on Tuesday, May 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $51.00 price target on shares of Hologic in a research note on Friday, July 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and a consensus target price of $48.64.

In other Hologic news, Director Elaine Ullian sold 6,902 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now directly owns 23,810 shares in the company, valued at $955,257.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. Insiders have sold 60,627 shares of company stock worth $2,632,911 over the last 90 days. 0.79% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.